Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT05216432 2025-09-22

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Phase 1 Recruiting

930 enrolled

Breast

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

200 enrolled

Breast

Breast Neoplasms

NCT05870579 2025-08-21

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Recruiting

48 enrolled

Breast

Breast Neoplasms

NCT05759949 2025-05-16

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Phase 1 Completed

41 enrolled

Breast

Breast Neoplasms

NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1 Terminated

241 enrolled

DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

6 enrolled

Breast

Breast Neoplasms

NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Phase 1 Completed

88 enrolled

Breast

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Phase 1 Terminated

199 enrolled

Breast

Advanced or Metastatic ER+ Breast Cancer

NCT01857193 2021-04-13

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Phase 1 Completed

132 enrolled

Breast

Breast Neoplasms

NCT02703571 2020-12-21

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Phase 1 Terminated

95 enrolled

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT01898845 2020-12-19

A Phase I Study of LEE011 in Asian Patients

Phase 1 Completed

17 enrolled

Tumor-Agnostic

Neoplasms

NCT02154776 2020-12-19

LeeBLet

Phase 1 Completed

13 enrolled

Breast

Breast Neoplasms

NCT01237236 2020-12-17

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.

Phase 1 Completed

156 enrolled

Lymphoid

Lymphoma

NCT02088684 2020-12-17

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Phase 1 Completed

70 enrolled

Breast

Breast Neoplasms

NCT02292550 2020-12-17

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Phase 1 Completed

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02343172 2020-12-09

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Phase 1 Completed

74 enrolled

Sarcoma

Liposarcoma

NCT01747876 2019-11-22

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Phase 1 Terminated

32 enrolled 14 charts

CNS

Neuroblastoma

Clinical Trials

Study of INCB123667 in Subjects With Advanced Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

SERENA-1

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

(VELA) Study of BLU-222 in Advanced Solid Tumors

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

PIKture-01

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

A Phase I Study of LEE011 in Asian Patients

LeeBLet

A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma